The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of ...
"TECVAYLI is the only BCMA-targeted immune-based therapy with weight-based dosing. Today's approval of biweekly dosing for eligible patients will further enable clinicians to meet the individual needs ...
Some people are overdosing from certain products marketed for weight loss, federal health officials are warning. The FDA has received reports of dosing errors involving compounded semaglutide ...
Doses of 0.6 and 1.2 mg ZP8396 administered once-weekly for six weeks led to 5.3% and 5.1% mean weight loss as compared to 2.6%, 3.6% and 4.2% weight loss following single doses of 0.7, 1.4 and 2.4 mg ...
Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. A reduced dosing schedule of Tecvayli (teclistamab) continued to slow the progression of ...
C4 Therapeutics has learned a lot from just five multiple myeloma patients reporting out from the first cohort in a phase 1 trial of its lead candidate, a IKZF1/3 degrader called CFT7455. For starters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results